AU2001234420A1 - Potentiators of glutamate receptors - Google Patents

Potentiators of glutamate receptors

Info

Publication number: AU2001234420A1
Authority: AU; Australia
Prior art keywords: potentiators; glutamate receptors; glutamate; receptors
Prior art date: 2000-02-03
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU2001234420A

Inventor

David Anthony Barda

Thomas Charles Britton

Darrell Stephen Coleman

Bruce Anthony Dressman

Michael William Fichtner

Steven Scott Henry

William Joseph Hornback

Gunnar Erik Junior Jagdmann

Kirk Willis Johnson

Michael Parvin Johnson

Thomas Hallett Large

James Allen Monn

Darryle Darwin Schoepp

Joseph Patrick Tizzano

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Eli Lilly and Co

Original Assignee

Eli Lilly and Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-02-03

Filing date

2001-01-22

Publication date

2001-08-14

2001-01-22 Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co

2001-08-14 Publication of AU2001234420A1 publication Critical patent/AU2001234420A1/en

Status Abandoned legal-status Critical Current

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
- C07D213/643—2-Phenoxypyridines; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

AU2001234420A 2000-02-03 2001-01-22 Potentiators of glutamate receptors Abandoned AU2001234420A1 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US18004700P	2000-02-03	2000-02-03
US18008900P	2000-02-03	2000-02-03
US60180089		2000-02-03
US60180047		2000-02-03
PCT/US2001/000643 WO2001056990A2 (en)	2000-02-03	2001-01-22	Pyridine derivates as potentiators of glutamate receptors

Publications (1)

Publication Number	Publication Date
AU2001234420A1 true AU2001234420A1 (en)	2001-08-14

Family

ID=26875939

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2001234420A Abandoned AU2001234420A1 (en)	2000-02-03	2001-01-22	Potentiators of glutamate receptors

Country Status (4)

Country	Link
US (1)	US6800651B2 (en)
EP (1)	EP1255735A2 (en)
AU (1)	AU2001234420A1 (en)
WO (1)	WO2001056990A2 (en)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR040456A1 (en)	2002-06-27	2005-04-06	Bristol Myers Squibb Co	PIRIDINE N-OXIDES 2,4-USEFUL DISPOSALS AS INHIBITORS OF REVERSE TRANSCRIPTASE OF THE HUMAN IMMUNODEFICIENCY VIRUS
EP1611096A4 (en) *	2003-03-26	2007-08-29	Merck & Co Inc	Benzamide modulators of metabotropic glutamate receptors
CA2549969A1 (en) *	2003-10-31	2005-05-19	Astrazeneca Ab	Alkynes ii
BRPI0508310A (en)	2004-03-02	2007-07-24	Hoffmann La Roche	4- (sulfanyl-pyrimidin-4-ylmethyl) -morpholine derivatives and related compounds as gaba receptor ligands, for the treatment of anxiety, depression and epilepsy
GB0420719D0 (en) *	2004-09-17	2004-10-20	Addex Pharmaceuticals Sa	Novel allosteric modulators
GB0420722D0 (en)	2004-09-17	2004-10-20	Addex Pharmaceuticals Sa	Novel allosteric modulators
US20070287716A1 (en) *	2004-10-28	2007-12-13	Hu Essa H	Pyrimidine and Quinoline Potentiators of Metabotropic Glutamate Receptors
PL1817301T3 (en)	2004-11-22	2012-08-31	Lilly Co Eli	Potentiators of glutamate receptors
EP1828199B1 (en)	2004-12-17	2009-05-06	F. Hoffmann-Roche AG	Thieno-pyridine derivatives as gaba-b allosteric enhancers
JP2008536802A (en)	2005-02-24	2008-09-11	メルクエンドカムパニーインコーポレーテッド	Benzazole potentiator of metabotropic glutamate receptor
BRPI0611516A2 (en)	2005-06-02	2010-09-14	Hoffmann La Roche	3-methanesulfonylquinolines as enhancers of gaba-b
MX2007015729A (en) *	2005-06-09	2008-02-21	Schering Plough Ltd	Control of parasites in animals by n-[(phenyloxy)phenyl]-1,1,1-tr ifluoromethanesulfonamide and n-[(phenylsulfanyl)phenyl]-1,1,1-tr ifluoromethanesulfonamide derivatives.
MX2007015287A (en) *	2005-06-09	2008-02-22	Mallinckrodt Inc	Method for separation and purification of naltrexone by preparative chromatography.
AR057455A1 (en) *	2005-07-22	2007-12-05	Merck & Co Inc	INHIBITORS OF HIV REVERSE TRANSCRIPTASE AND PHARMACEUTICAL COMPOSITION
BRPI0614920A2 (en)	2005-07-28	2011-04-19	Hoffmann La Roche	2-hydroxy-propionic acid derivatives and 3-hydroxy-benzofuran-2-one derivatives with gaba-b-receptor affinity
JP2009506069A (en)	2005-08-26	2009-02-12	ブレインセルス，インコーポレイティド	Neurogenesis through modulation of muscarinic receptors
EP2258357A3 (en)	2005-08-26	2011-04-06	Braincells, Inc.	Neurogenesis with acetylcholinesterase inhibitor
AU2006304787A1 (en)	2005-10-21	2007-04-26	Braincells, Inc.	Modulation of neurogenesis by PDE inhibition
US20070112017A1 (en)	2005-10-31	2007-05-17	Braincells, Inc.	Gaba receptor mediated modulation of neurogenesis
AU2007223036A1 (en) *	2006-03-08	2007-09-13	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
US20100216734A1 (en) *	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
TWI417095B (en)	2006-03-15	2013-12-01	Janssen Pharmaceuticals Inc	1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of mglur2-receptors
EP2021000A2 (en)	2006-05-09	2009-02-11	Braincells, Inc.	Neurogenesis by modulating angiotensin
JP2009536667A (en)	2006-05-09	2009-10-15	ブレインセルス，インコーポレイティド	5HT receptor-mediated neurogenesis
US20100009983A1 (en) *	2006-05-09	2010-01-14	Braincells, Inc.	5 ht receptor mediated neurogenesis
US7998971B2 (en) *	2006-09-08	2011-08-16	Braincells Inc.	Combinations containing a 4-acylaminopyridine derivative
US20080103165A1 (en) *	2006-09-19	2008-05-01	Braincells, Inc.	Ppar mediated modulation of neurogenesis
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
JP2010509392A (en) *	2006-11-13	2010-03-25	ファイザー・プロダクツ・インク	Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof
TW200900065A (en)	2007-03-07	2009-01-01	Janssen Pharmaceutica Nv	3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200900391A (en) *	2007-03-07	2009-01-01	Janssen Pharmaceutica Nv	3-cyano-4-(4-phenyl-piperidin-1-yl)-pyridin-2-one derivatives
TW200845978A (en)	2007-03-07	2008-12-01	Janssen Pharmaceutica Nv	3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
EP2150244A1 (en) *	2007-04-23	2010-02-10	House Ear Institute	Treatment and/or prevention of presbycusis by modulation of metabotropic glutamate receptor 7
EP2167464B1 (en) *	2007-05-25	2014-12-03	AbbVie Deutschland GmbH & Co KG	Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mglu2 receptor)
WO2009004430A1 (en)	2007-06-29	2009-01-08	Pfizer Inc.	N-benzyl oxazolidinones and related heterocycleic compounds as potentiators of glutamate receptors
TW200922566A (en)	2007-09-14	2009-06-01	Ortho Mcneil Janssen Pharm	1,3 disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones
JP5433579B2 (en)	2007-09-14	2014-03-05	ジャンセンファーマシューティカルズ，インコーポレイテッド．	1,3-disubstituted-4-phenyl-1H-pyridin-2-one
TWI445532B (en) *	2007-09-14	2014-07-21	Janssen Pharmaceuticals Inc	1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h, 1'h-[1,4'] bipyridinyl-2'-ones
ES2637794T3 (en)	2007-11-14	2017-10-17	Janssen Pharmaceuticals, Inc.	Imidazo [1,2-A] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
CN101952274A (en) *	2007-11-20	2011-01-19	默沙东公司	Non-nucleoside reverse transcriptase inhibitor
TW201006801A (en)	2008-07-18	2010-02-16	Lilly Co Eli	Imidazole carboxamides
CA2735764C (en)	2008-09-02	2016-06-14	Ortho-Mcneil-Janssen Pharmaceuticals, Inc.	3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
ES2466341T3 (en)	2008-10-16	2014-06-10	Janssen Pharmaceuticals, Inc.	Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
US8389500B2 (en) *	2008-10-30	2013-03-05	Gilead Sciences, Inc.	Fused heterocyclic compounds as ion channel modulators
WO2010060589A1 (en)	2008-11-28	2010-06-03	Ortho-Mcneil-Janssen Pharmaceuticals, Inc.	Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
ES2397934T3 (en)	2008-12-17	2013-03-12	Amgen Inc.	Aminopyridine and carboxypyridine compounds as phosphodiesterase 10 inhibitors
WO2010099217A1 (en)	2009-02-25	2010-09-02	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
EP2425249B1 (en)	2009-04-30	2014-07-16	Cisbio Bioassays	Method for detecting compounds modulating dimers of vft domain membrane proteins
SG176018A1 (en)	2009-05-12	2011-12-29	Janssen Pharmaceuticals Inc	1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
MX2011011964A (en)	2009-05-12	2012-02-23	Janssen Pharmaceuticals Inc	1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders.
MY153913A (en)	2009-05-12	2015-04-15	Janssen Pharmaceuticals Inc	7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
ES2536433T3 (en)	2010-11-08	2015-05-25	Janssen Pharmaceuticals, Inc.	1,2,4-Triazolo [4,3-a] pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
JP5852666B2 (en)	2010-11-08	2016-02-03	ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド	1,2,4-Triazolo [4,3-a] pyridine derivatives and their use as positive allosteric modulators of the mGluR2 receptor
PL2649069T3 (en)	2010-11-08	2016-01-29	Janssen Pharmaceuticals Inc	1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
EP2968359B1 (en)	2013-03-12	2021-01-20	Celltaxis, LLC	Methods of inhibiting leukotriene a4 hydrolase
EP2970309A4 (en)	2013-03-14	2016-11-09	Celtaxsys Inc	Inhibitors of leukotriene a4 hydrolase
EP2968265A4 (en) *	2013-03-14	2016-12-28	Celtaxsys Inc	Inhibitors of leukotriene a4 hydrolase
EP2968264A4 (en)	2013-03-14	2016-11-02	Celtaxsys Inc	Inhibitors of leukotriene a4 hydrolase
JO3368B1 (en)	2013-06-04	2019-03-13	Janssen Pharmaceutica Nv	6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
JO3367B1 (en)	2013-09-06	2019-03-13	Janssen Pharmaceutica Nv	1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
UA127921C2 (en)	2014-01-21	2024-02-14	Янссен Фармацевтика Нв	Combinations containing positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
DK3096790T3 (en)	2014-01-21	2019-10-07	Janssen Pharmaceutica Nv	COMBINATIONS INCLUDING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROP GLUTAMATERG SUBTYPE 2 RECEPTOR AND APPLICATION OF THESE
WO2017001936A2 (en) *	2015-07-01	2017-01-05	Lifesci Pharmaceuticals, Inc.	Therapeutic inhibitory compounds
WO2017005710A1 (en) *	2015-07-08	2017-01-12	Bayer Cropscience Aktiengesellschaft	Phenoxyhalogenphenylamidines and the use thereof as fungicides
AU2019278935A1 (en)	2018-05-31	2020-12-10	Celltaxis, Llc	Method of reducing pulmonary exacerbations in respiratory disease patients
EP3952853A4 (en) *	2019-04-12	2023-04-12	Tonix Pharmaceuticals Holding Corp.	Inhibitors of cd40-cd154 binding
EP4299124A1 (en)	2022-06-30	2024-01-03	Universite De Montpellier	Anti-mglur2 nanobodies for use as biomolecule transporter

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3923992A (en) *	1974-05-23	1975-12-02	Univ Mississippi	Analgetic composition and method of use
DE2557425A1 (en)	1975-12-19	1977-06-30	Boehringer Sohn Ingelheim	CHINAZOLONE DERIVATIVES
GB2056974B (en)	1979-07-19	1984-02-29	Shell Int Research	Heterocyclic acylamino compounds having fungicidal herbicidal and plant-growth regulating properties
GB8311003D0 (en) *	1983-04-22	1983-05-25	Shell Int Research	Aniline compounds
US4644069A (en) *	1984-08-15	1987-02-17	Ciba-Geigy Corporation	Process for the preparation of dimethylmaleic anhydride
US4874775A (en) *	1985-06-11	1989-10-17	Eli Lilly And Company	Agriculturally useful sulfonamides
US4855308A (en) *	1987-12-04	1989-08-08	Warner-Lambert Company	Method of treating senile cognitive decline with N'-substituted aminopyridine adrenergic agents
AU6812790A (en) *	1989-12-22	1991-06-27	Ici Americas Inc.	Fungicidal compounds
DE4308395A1 (en) *	1993-03-17	1994-09-22	Basf Ag	Pest control procedures
AU3414295A (en)	1994-08-19	1996-03-14	Nps Pharmaceuticals, Inc.	Methods and compounds active at metabotropic glutamate receptors useful for treatment of neurological disorders and diseases
GB9702194D0 (en) *	1997-02-04	1997-03-26	Lilly Co Eli	Sulphonide derivatives
ES2186186T3 (en) *	1997-08-04	2003-05-01	Taisho Pharmaceutical Co Ltd	ARYLOXIANILINE DERIVATIVES.
JP2959765B2 (en) *	1997-12-12	1999-10-06	日本たばこ産業株式会社	3-piperidyl-4-oxoquinazoline derivative and pharmaceutical composition containing the same
CA2322139A1 (en) *	1998-02-24	1999-09-02	Eli Lilly And Company	Sulphonamide derivatives
JP2000001476A (en)	1998-06-15	2000-01-07	Taisho Pharmaceut Co Ltd	Aryloxy nitrogen-containing arylamine derivative
WO2008060428A2 (en)	2006-11-09	2008-05-22	Wms Gaming Inc.	Substantially transparent electrical components within a wagering game machine

2001
- 2001-01-22 US US10/182,961 patent/US6800651B2/en not_active Expired - Fee Related
- 2001-01-22 WO PCT/US2001/000643 patent/WO2001056990A2/en not_active Application Discontinuation
- 2001-01-22 AU AU2001234420A patent/AU2001234420A1/en not_active Abandoned
- 2001-01-22 EP EP01906521A patent/EP1255735A2/en not_active Withdrawn

Also Published As

Publication number	Publication date
US20040006114A1 (en)	2004-01-08
EP1255735A2 (en)	2002-11-13
WO2001056990A3 (en)	2002-04-25
US6800651B2 (en)	2004-10-05
WO2001056990A2 (en)	2001-08-09

Publication	Publication Date	Title
AU2001234420A1 (en)	2001-08-14	Potentiators of glutamate receptors
AU2002363005A1 (en)	2003-05-06	Derivatives of uk-2a
AU2001227839A1 (en)	2001-07-24	Shower head
AU2002221047A1 (en)	2002-06-24	Quinazolinone derivatives
AU2002235211A1 (en)	2002-06-24	Shower head assembly
AU2001230584A1 (en)	2001-08-20	1h-imidazopyridine derivatives
AU2001243345A1 (en)	2001-09-12	1983, 52881, 2398, 45449, 50289, and 52872, g protein-coupled receptors and uses therefor
AU2002212436A1 (en)	2002-05-06	Quinazoline derivatives
AU2002352444A1 (en)	2003-07-09	Quinazolinedione derivatives
AU2001231664A1 (en)	2001-11-01	Indol-3-yl derivatives
AU2001292137A1 (en)	2002-04-22	Quinazoline derivatives
AU2002212982A1 (en)	2002-04-08	Dynamic swing voltage adjustment
AU2001244646A1 (en)	2002-05-27	Small drill
AU2002213978A1 (en)	2002-06-27	Substituted C-cyclohexylmethylamine derivatives
AU2002362806A1 (en)	2003-07-03	Pyrimidine derivatives
AU2002310384A1 (en)	2003-01-02	End anchors
AU2001268701A1 (en)	2002-01-21	Methods of enhancing adhesion
AU2001274265A1 (en)	2002-01-02	Sulphonamide derivatives
AU2001289937A1 (en)	2002-06-27	Substituted 1-aminobutan-3-ol derivatives
AU2001230565A1 (en)	2001-08-14	Perfluoroisopropylbenzene derivatives
AU2001258533A1 (en)	2001-11-26	Construction of dies
AU2001242772A1 (en)	2001-10-03	3-substituted-4-pyrimidone derivatives
AU2002338989A1 (en)	2003-05-08	Substituted C-furan-2-yl-methylamine and C-thiophen-2-yl-methylamine derivatives
AU2002214681A1 (en)	2002-05-15	Hypertension
AU2002230744A1 (en)	2002-07-01	Tapered microkeratome head